Caris Life Sciences, Inc.

CAI

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

OrbiMed Advisors Perceptive Advisors Rock Springs Capital

Catalysts

No catalysts tracked.

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 3,116,011Value: $84.1M

**Signal Note: OrbiMed Initiates $84M Position in Caris Life Sciences** OrbiMed's new $84M stake in Caris likely reflects confidence in the company's precision oncology platform expansion, particularly its liquid biopsy and tumor profiling capabilities that drive companion diagnostic adoption across multiple indications. The timing suggests potential catalysts including expanded payer coverage for its CircumDx cfDNA test, commercial traction in early-stage cancer detection, or upcoming data readouts from its diagnostic-driven clinical programs.

Perceptive AdvisorsNEW

More CAI Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NBIX3 funds FOLD3 funds ASND3 funds DYN3 funds ISRG3 funds BSX3 funds EXAS3 funds XENE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: Perceptive Advisors Initiates $30.7M Position in Caris Life Sciences Perceptive's entry into CAI signals confidence in Caris's precision oncology platform, likely driven by expanding adoption of its tumor profiling services (Whole Exome Sequencing, Whole Genome Sequencing) across solid tumors and potential catalysts from pipeline programs in immuno-oncology. Edelman's clinical-stage track record suggests conviction in near-term data readouts or commercial inflection, though Caris's primary value currently derives from growing service revenues rather than approved therapeutics. Monitor for 2024-2025 guidance raises and any advancement of CAI's proprietary drug candidates (e.g., CARINA-2 in ovarian cancer) as validation events.